Immuneering Corporation (IMRX) - What Are Investment Firms Thinking About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Six firms rate Immuneering “Moderate Buy,” including four buys and one strong buy, with an average 12-month price target of $15.67.
• Institutional ownership is substantial: Institutional investors and hedge funds own 67.65% of IMRX, while several firms recently initiated or increased positions.
• The stock remains under pressure: IMRX opened at $3.49, near its 52-week low of $3.38, and the company reported a quarterly EPS loss of $0.37, missing estimates by $0.06.

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $15.67.

Several analysts have commented on the stock. Mizuho set a $11.00 target price on shares of Immuneering in a research report on Thursday. Needham & Company LLC raised their price target on Immuneering from $11.00 to $18.00 and gave the stock a "buy" rating in a research report on Monday, July 20th. HC Wainwright reiterated a "buy" rating on shares of Immuneering in a report on Friday. Chardan Capital raised Immuneering to a "strong-buy" rating in a research note on Monday, August 3rd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Immuneering in a report on Monday, September 21st.

Institutional Trading of Immuneering

Hedge funds have recently modified their holdings of the company. Integrated Wealth Concepts LLC acquired a new stake in Immuneering in the second quarter worth $34,000. Levin Capital Strategies L.P. bought a new position in shares of Immuneering during the first quarter worth $53,000. VestGen Advisors LLC grew its holdings in shares of Immuneering by 100.0% in the 3rd quarter. VestGen Advisors LLC now owns 20,002 shares of the company's stock valued at $82,000 after buying an additional 10,002 shares during the period. Focus Financial Network Inc. acquired a new position in shares of Immuneering in the 2nd quarter valued at $62,000. Finally, Principle Wealth Partners LLC acquired a new position in shares of Immuneering in the 3rd quarter valued at $51,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Immuneering Price Performance

IMRX opened at $3.49 on Tuesday. The firm has a 50 day simple moving average of $4.25 and a 200 day simple moving average of $4.79. Immuneering has a fifty-two week low of $3.38 and a fifty-two week high of $8.48. The company has a market cap of $225.80 million, a price-to-earnings ratio of -3.39 and a beta of 0.46.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.06). As a group, analysts expect that Immuneering will post -1.09 EPS for the current year.

About Immuneering

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering's lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.